Patient Financing for CFOs: What Matters and What Doesn’t

Key Takeaways

• Patient financing is a balance-sheet decision, not a front-desk convenience. The structure you choose shapes risk exposure, cash flow, and how predictable your revenue really is.
• What matters most: non-recourse funding, approval rates that hold up in the real world, full treatment coverage, transparent fees, and how fast the money actually shows up.
• What matters far less than most providers assume: brand recognition, the lowest number on a rate sheet, or a financing menu with a dozen products on it.
• Every specialty has its own pressure points worth building into how you evaluate a partner. Dental, orthodontics, MedSpa, vision, audiology, and veterinary all look a little different.
• A good financing partner cuts risk and administrative burden at the same time. If a program is adding work for your team, or adding a liability to your books, it isn’t doing its job.

Why This Is Really a CFO Decision

Patient financing has a way of getting treated like a front-desk tool, something the treatment coordinator picked because a rep gave a good demo and the sign-up was easy. For a single-location practice, maybe that’s fine. But once out-of-pocket costs make up a real share of revenue, or you’re managing this across multiple locations, that decision belongs higher up the chain than it usually sits.

Here’s why. The financing model a practice runs touches case acceptance, days-to-cash, chargeback exposure, reserve requirements, and merchant fees, all things that eventually land on a CFO’s desk whether or not they were part of the original decision. Done well, financing becomes a genuine growth lever. Patients say yes to treatment they’d otherwise put off, and revenue arrives in a way you can actually forecast. Done poorly, you’ve added risk to the business that stays invisible right up until a patient defaults, or a program’s fine print turns out to matter more than anyone realized at signing.

And the stakes here aren’t shrinking. As deductibles climb and coverage gaps widen, more of the total cost of care keeps landing directly on the patient. Every year that shift continues, the financing decision carries a little more weight on your books.

What Actually Matters

Non-recourse risk transfer

If there’s one lever that matters more than the others, it’s this one. It’s also the one that gets glossed over most often in a sales pitch.

Non-recourse means once your practice is paid, you’re paid. The financing company takes on the risk if a patient stops making payments. Recourse means your practice can still be on the hook for chargebacks, clawbacks, or reserve requirements, even after the initial payout lands in your account.

For a CFO, that distinction isn’t a technicality buried in the terms. It’s the difference between revenue you can actually plan around and a contingent liability you’ll have to explain later. Here’s a fuller breakdown of how non-recourse financing works if you want to dig into the mechanics.

Approval rates that hold up outside the sales deck

Every financing company will show you an impressive approval number. What actually matters is whether that number holds across your patient base, not just the patients with pristine credit, but the ones with thin files or a rough patch a few years back who would absolutely have paid you back.

A program built on generic retail credit underwriting screens out a lot of those patients. That shows up on your books as lost treatment plans, not as a line item labeled “underwriting problem.” That’s exactly why it’s easy for CFOs to miss.

Full coverage, not partial approval

Nothing puts your team in a worse spot than a financing partner that covers half a treatment plan and leaves the rest to the patient. Now someone has to ask the patient to cover the difference out of pocket, or talk them into a scaled-down version of the plan, or just lose the case. None of those are good outcomes. Look for a program built to fund the whole cost of care, not just the comfortable middle of it.

This is also where a lot of CFOs get sold a number that doesn’t hold up. “Zero down payment” sounds like the better deal on paper, and plenty of lenders lead with it. But zero down doesn’t mean much if the approval behind it only covers a fraction of the treatment. Say a patient needs $7,000 in care. HFD might approve that patient for the full $7,000 with a $499 down payment. Another lender might approve the same patient for $700 with $0 down, then turn around and tell your team that HFD’s down payments run too high. That’s not really a comparison. It’s a bit of a sleight of hand, and it’s worth watching for anytime a competitor’s pitch leans hard on “no down payment” without also stating what percentage of the treatment plan actually gets covered. The number that should drive the comparison is total approved amount against total treatment cost, not the down payment figure by itself. (We’re building out a dedicated piece on exactly this. Link coming soon.)

What the financing actually costs, once you add it all up

Merchant fees, patient APR, origination costs, and whatever reconciliation work your billing team ends up doing all add up to the real cost of a program, and it’s not always visible in the first conversation. A low headline rate paired with confusing fee tiers or unclear handling of refunds and early payoffs can end up costing more, in both margin and staff time, than a program with a simpler and fully transparent structure.

Ask for the fee schedule in writing. Ask specifically how fees work on partial payments, early payoffs, and refunds, not just the standard case everyone leads with.

How fast you actually get paid

Cash flow is cash flow. A program that takes weeks to fund, or funds unpredictably, makes forecasting harder and makes it tougher to reinvest in the practice with any confidence. Ask how many business days after treatment you’re actually paid, and whether that timeline holds steady or moves around.

The lending structure behind the program

Who’s actually extending the credit? Is there a bank behind this program, and if so, which one? And under what regulatory framework? For multi-location groups and DSOs especially, this is a compliance question as much as a financial one. Ask for the issuing bank, NMLS registration, and how the program handles the fact that lending rules aren’t identical from state to state.

It’s also worth asking how the lender is capitalized, and not treating that as a formality. Patient financing has seen a fair amount of churn over the past several years. Lenders have entered the space, scaled quickly, and then exited or pulled back when funding got tight. When that happens, the practices relying on them are the ones left scrambling, mid-relationship, to find a new financing partner and explain the disruption to patients already in the middle of a payment plan. A lender backed by a single capital source is more exposed to that kind of disruption. One built on multiple, diversified capital partners has more room to absorb market pressure without pulling back on approvals or exiting the business altogether. It’s a quieter risk than approval rates or fees, but it’s a real one. Ask who’s behind the capital, not just who’s behind the brand.

What it takes from your staff

Every extra step in a financing workflow costs something, even when it never shows up as its own line item. A clunky application, a slow approval process, or a platform that doesn’t talk to the rest of your systems all add friction. And friction shows up as lower case acceptance and more staff time per patient. In-house financing has its own set of trade-offs worth weighing here too, so it’s worth comparing directly against third-party options rather than assuming one is obviously right.

What Matters Less Than You’d Think

A lot of the time spent evaluating financing partners goes toward things that sound important but rarely change the outcome.

Brand recognition. A familiar name doesn’t tell you whether the underwriting is built for healthcare, or whether it fits your patient mix. Structure matters more than familiarity; not every program is built the same way, even when the names sound similar.

The lowest number on the rate sheet. A low advertised rate paired with tight approvals or recourse exposure can end up costing more, in lost case acceptance and balance-sheet risk, than a slightly higher rate that comes with broader approvals and non-recourse protection.

A long menu of financing products. More options can look like flexibility on a sales slide. In practice, it usually means more complexity for the front desk and a less consistent experience for patients. One plan that works for nearly everyone beats five overlapping ones that confuse the team trying to explain them.

Promotional gimmicks. 0% APR can absolutely be part of a good program. It shouldn’t be the reason you pick one. See what a 0% APR program actually involves before you let it be the deciding factor.

A Quick Guide by Specialty

Every vertical carries its own cost range, patient expectations, and financing friction points. Here’s a fast rundown for CFOs in each industry.

Dental & DSOs. Treatment plans range from a single crown to full-mouth reconstruction, and for DSOs, consistency across locations matters almost as much as the approval rate itself. A program that performs differently office to office makes forecasting and reporting a headache at the corporate level. More on dental financing here.

Orthodontics & Invisalign. These cases usually get presented as one large plan rather than a series of smaller procedures, which makes full-coverage approval especially important. A partial approval here often means losing the case outright, not just scaling it back.

MedSpa & Aesthetics. Elective, often repeat business, so patient experience and approval speed carry real weight for return visits. A partner that makes it just as easy to finance the third treatment as the first supports the relationship, not just a single transaction. More on MedSpa financing here.

Veterinary. Decisions here often happen in urgent, emotional moments. Speed and simplicity matter more in this vertical than almost anywhere else. Pet owners need an answer in minutes, not days.

Optometry & Vision. A mix of routine purchases and bigger one-time procedures (LASIK, for instance) inside the same patient relationship. A program flexible enough to handle both without forcing separate financing conversations is worth more than it might seem.

Audiology. Hearing care is frequently underinsured, and delaying treatment has real quality-of-life consequences. Approval rates for patients with limited or thin credit history matter more here than in most other verticals, since the patient population skews toward fixed or limited incomes.

Questions Worth Asking Before You Sign

A short list to bring into any vendor conversation:

1. Is this program recourse or non-recourse, and what does that actually mean for our balance sheet?
2. What’s our real approval rate across our patient population, not the number from the marketing deck?
3. Does this fund full treatment plans, or partial amounts?
4. Can I see the complete fee schedule, including edge cases like refunds and early payoff?
5. How many business days after treatment do we get paid, and how consistent is that?
6. Who’s the issuing bank or lender, and what’s the regulatory structure behind this? How is the lender capitalized?
7. What will onboarding and staff training actually require from our team?

Helpful FAQ

What’s the difference between recourse and non-recourse patient financing?

In non-recourse financing, the lender takes on the risk if a patient defaults. Once your practice is paid, that’s final. In recourse financing, your practice can retain some liability for unpaid balances, which may mean reserves or ongoing balance-sheet exposure.

Does offering patient financing affect our practice’s own credit or compliance standing?

Reputable third-party financing generally doesn’t show up as practice debt the way a business loan would. Even so, it’s worth confirming the issuing bank, lending structure, and compliance framework as part of your due diligence. Don’t take that on faith.

How fast should we expect to be paid after a patient is approved and treatment is done?

It varies by provider, but a well-run program typically funds within a few business days. Ask for a specific, guaranteed timeline rather than a vague estimate. “Usually pretty fast” isn’t an answer you can forecast against.

Is a higher advertised approval rate always the better choice?

Not necessarily. Context matters here, including what the approval actually covers (full treatment or partial), how it performs across your real patient mix, and what risk sits behind it. A high approval rate with recourse exposure attached can still be the worse deal compared to a slightly lower rate with non-recourse protection.

Should DSOs and multi-location groups evaluate financing differently than a single practice would?

Yes. Consistency across locations, centralized reporting, and predictable funding timelines matter more at scale. Inconsistent performance from office to office complicates both forecasting and compliance review.

Patient financing carries more financial weight than it usually gets credit for. The practices that treat this as a CFO-level decision, not just something the front desk figures out, tend to see it pay off in stronger case acceptance, more predictable cash flow, and a lot less risk sitting quietly on the books.

See how HFD is built specifically for healthcare financing, or request a demo and we’ll walk through approval rates, funding timelines, and program structure for your practice directly.